Advertisement

Overcoming the barriers to HPV vaccination in high-risk populations in the U.S.: A Society of Gynecologic Oncology (SGO) Review

      Highlights

      • Public health education with media campaigns centered around HPV health risks and vaccine safety
      • Public health funding allowing widespread access for all adolescents and young adults
      • Education and incentives for primary healthcare providers to vaccinate
      • HPV vaccine mandates or school-based vaccination
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Senkomago V.
        • Henley S.J.
        • Thomas C.C.
        • Mix J.M.
        • Markowitz L.E.
        • Saraiya M.
        Human papillomavirus–attributable cancers — United States, 2012–2016.
        MMWR Morb. Mortal. Wkly Rep. 2019; 68: 724-728
      1. https://www.cdc.gov/mmwr/volumes/68/wr/mm6832a3.htm CDC vaccination for Adults recommendations.

        • Lichter K.
        • Krause D.
        • Xu J.
        • Tsai S.H.L.
        • Hage C.
        • Weston E.
        • Eke A.
        • Levinson K.
        Adjuvant human papillomavirus vaccine to reduce recurrent cervical dysplasia in unvaccinated women: a systematic review and meta-analysis.
        Obstet. Gynecol. 2020; 135: 1070
        • Walling E.B.
        • et al.
        Interventions to improve HPV vaccine uptake: a systematic review.
        Pediatrics. 2016; 138
        • Lei J.
        • et al.
        HPV vaccination and the risk of invasive cervical cancer.
        NEJM. 2020; 383 (PMID 32997908): 1340-1348
        • Colgrove James
        • Sara Abiola
        • Michelle M Mello
        HPV Vaccination Mandates — Lawmaking amid Political and Scientific Controversy.
        N. Engl. J. Med. 2010; 363: 785-791
        • Walker T.Y.
        • Elam-Evans L.D.
        • Yankey D.
        • et al.
        National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years - United States, 2017.
        MMWR Morb. Mortal. Wkly Rep. 33, 2018; 67: 909-917
        • Miller K.
        • Dilley S.E.
        W.K. Huh Lessons learned from domestic and international human papillomavirus vaccination programs: a review Am.
        J. Obstet. Gynecol. 2018 May; 218: 467-473
        • US Department of Health and Human Services OoDPaHP
        US department of health and human services, & office of disease prevention and health promotion Healthy people.
        2010. 2020
        • Walker T.Y.
        • et al.
        Trends in human papillomavirus (HPV) vaccination initiation among adolescents aged 13–17 by metropolitan statistical area (MSA) status, National Immunization Survey - Teen, 2013–2017.
        Hum Vaccin Immunother. 2019; : 1-8
        • Tsai Y.
        • et al.
        Insurance reimbursements for human papillomavirus vaccination in the private sector, 2007-2014.
        Prev. Med. Rep. 2019; 15: 100917
        • Organization, W.H
        Global Market Study HPV.
        2018
        • Arie S.
        HPV: WHO calls for countries to suspend vaccination of boys.
        BMJ. 2019; 367: l676
        • Rodriguez A.M.
        • et al.
        Comparison of the long-term impact and clinical outcomes of fewer doses and standard doses of human papillomavirus vaccine in the United States: a database study.
        Cancer. 2020 Apr 15; 126: 1656-1667
        • Attia A.C.
        • Wolf J.
        • Nunez A.E.
        On surmounting the barriers to HPV vaccination: we can do better.
        Ann. Med. 2018; 50: 209-225
        • Thompson E.L.
        • Livingston 3rd, M.D.
        • Daley E.M.
        • Zimet G.D.
        Human papillomavirus vaccine initiation for adolescents following Rhode Island's school-entry requirement, 2010-2016.
        Am. J. Public Health. 2018; 108: 1421-1423
        • Prevention CfDCa
        SUPPLEMENTARY TABLE 3. Estimated vaccination coverage with selected vaccines and doses among adolescents aged 13–17 years by HHS Region, state, selected local area, or territory — National Immunization Survey–Teen (NIS-Teen), United States, 2018.
        2018
        • Perkins R.B.
        • Lin M.
        • Wallington S.F.
        • Hanchate A.D.
        Impact of school-entry and education mandates by states on HPV vaccination coverage: analysis of the 2009-2013 National Immunization Survey-Teen.
        Hum Vaccin Immunother. 2016; 12: 1615-1622
        • Daley E.
        • Thompson E.
        • Zimet G.
        Human papillomavirus vaccination and school entry requirements: politically challenging, but not impossible.
        JAMA Pediatr. 2019; 173: 6-7
        • Laserson A.K.
        • et al.
        HPV vaccine and college-age men: a scoping review.
        Am. J. Mens Health. 2020; 14 (PMID 33225805)
        • Schuchat A.
        HPV "coverage".
        N. Engl. J. Med. 2015; 372: 775-776
        • Cartmell K.B.
        • Young-Pierce J.
        • McGue S.
        • Alberg A.J.
        • Luque J.S.
        • Zubizarreta M.
        • et al.
        Barriers, facilitators, and potential strategies for increasing HPV vaccination: a statewide assessment to inform action.
        Papillomavirus Res. 2018; 5: 21-31
        • Calo W.A.
        • Shah P.D.
        • Gilkey M.B.
        • Vanderpool R.C.
        • Barden S.
        • Doucette W.R.
        • et al.
        Implementing pharmacy-located HPV vaccination: findings from pilot projects in five U.S. states.
        Hum Vaccin Immunother. 2019; 15: 1831-1838
      2. Prevention CfDCa. HPV Vaccination Coverage Data.

        • Organization WH
        Ten Threats to Global Health in 2019.
        2019
        • Massey P.M.
        • Leader A.
        • Yom-Tov E.
        • Budenz A.
        • Fisher K.
        • Klassen A.C.
        Applying multiple data collection tools to quantify human papillomavirus vaccine communication on twitter.
        J. Med. Internet Res. 2016; 18e318
        • Ekram S.
        • Debiec K.E.
        • Pumper M.A.
        • Moreno M.A.
        Content and Commentary: HPV Vaccine and YouTube.
        J. Pediatr. Adolesc. Gynecol. 2019 Apr; 32: 153-157
        • Margolis M.A.
        • Brewer N.T.
        • Shah P.D.
        • Calo W.A.
        • Gilkey M.B.
        Stories about HPV vaccine in social media, traditional media, and conversations.
        Prev. Med. 2019; 118: 251-256
        • Teoh D.
        • Shaikh R.
        • Vogel R.I.
        • Zoellner T.
        • Carson L.
        • Kulasingam S.
        • et al.
        A cross-sectional review of cervical Cancer messages on twitter during cervical Cancer awareness month.
        J Low Genit Tract Dis. 2018; 22: 8-12
        • Mohanty S.
        • Leader A.E.
        • Gibeau E.
        • Johnson C.
        Using Facebook to reach adolescents for human papillomavirus (HPV) vaccination.
        Vaccine. 2018; 36 (Hansen PR, Schmidtblaicher M, Brewer NT. Resilience of HPV vaccine uptake in Denmark: Decline and recovery. Vaccine. 2020;38:1842-8): 5955-5961
        • Brouwer A.F.
        • Delinger R.L.
        • Eisenberg M.C.
        • Campredon L.P.
        • Walline H.M.
        • Carey T.E.
        • et al.
        HPV vaccination has not increased sexual activity or accelerated sexual debut in a college-aged cohort of men and women.
        BMC Public Health. 2019; 19: 821
      3. J.C. Spencer, W.A. Calo, N.T. Brewer Disparities and reverse disparities in HPV vaccination: a systematic review and meta-analysis, Prev. Med.., 123 (2019), pp. 197–203 [this reference is moved to later in paper and will need to be re-numbered].

        • Dilley S.
        • Miller K.M.
        • Huh W.K.
        Human papillomavirus vaccination: ongoing challenges and future directions.
        Gynecol. Oncol. 2020 Feb; 156: 498-502
        • Prevention CfDCa
        National, Regional, State and Selected Local Area Vaccination Coverage among adolescents aged 13-17 years—United States.
        Morb. Mortal. Wkly Rep. 2017; : 2017
        • Bednarczyk R.A.
        • et al.
        Health disparities in human papillomavirus vaccine coverage: trends analysis from the national immunization survey-teen, 2008-2011.
        Clin. Infect. Dis. 2014; 58 (PMID 31662024): 238-241
        • Kellogg C1.
        • Shu J.
        • Arroyo A.
        • Dinh N.T.
        • Wade N.
        • Sanchez E.
        • Equils O.
        A significant portion of college students are not aware of HPV disease and HPV vaccine recommendations.
        Hum Vaccin Immunother. 2019; 15: 1760-1766
        • Blasi P.R.
        • King D.
        • Henrikson N.B.
        HPV vaccine public awareness campaigns: an environmental scan.
        Health Promot. Pract. 2015 Nov; 16: 897-905
        • Keim-Malpass J.
        • Mitchell E.M.
        • DeGuzman P.B.
        • Stoler M.H.
        • Kennedy C.
        Legislative activity related to the human papillomavirus (HPV) vaccine in the United States (2006-2015): a need for evidence-based policy.
        Risk Manag Healthc Policy. 2017 Mar 13; 10: 29-32
        • Mroz S.
        • Zhang X.
        • Williams M.
        • Conlon A.
        • LoConte N.K.
        Working to increase vaccination for human papillomavirus: a survey of Wisconsin stakeholders, 2015.
        Prev. Chronic Dis. 2017 Sep 28; 14E85
        • McGhee E.
        • Harper H.
        • Ume A.
        • et al.
        Elimination of cancer health disparities through the acceleration of HPV vaccines and vaccinations: a simplified version of the president's cancer panel report on HPV vaccinations.
        J Vaccines Vaccin. 2017; 8
        • Paul P.
        A. Fabio Literature review of HPV vaccine delivery strategies: considerations for school- and non-school based immunization program.
        Vaccine. 2014; 32: 320-326
        • Haber G.
        • Malow R.M.
        • Zimet G.D.
        • et al.
        The HPV vaccine mandate controversy.
        J. Pediatr. Adolesc. Gynecol. 2007; 20: 325-331
        • Perkins R.B.
        • Pierre-Joseph N.
        • Marquez C.
        • et al.
        Parents' opinions of mandatory HPV vaccination: does ethnicity matter?.
        Womens Health Issues. 2010; 20: 420-426
        • Joura E.A.
        • Kyrgiou M.
        • Bosch F.X.
        • et al.
        Human papilloma virus vaccination: the ESGO-EFC position paper of the European society of Gynaecologic oncology and the European federation for colposcopy.
        Eur. J. Cancer. 2019; 116: 21-26
        • Friedman A.L.
        • Shepeard H.
        Exploring the knowledge, attitudes, beliefs, and communication preferences of the general public regarding HPV: findings from the CDC focus group research and implications for practice.
        Health Educ. Behav. 2007; 34: 471-485
      4. Public Health Rep. 2018; 133: 543-550
        • Goff B.
        Quality measures in gynecologic cancers: what and when?.
        Gynecol. Oncol. 2008; 110: 3-4
        • Bergman H.
        • Buckley B.S.
        • Villanueva G.
        • et al.
        Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males.
        Cochrane Databse Syst Rev. 2019; 11
        • Kreimer A.R.
        • Herrero R.
        • Sampson J.N.
        • et al.
        Evidence for single-dose protection by the bivalent HPV vaccine- review of the Costa Rica HPV vaccine trial and future research studies.
        Vaccine. 2018; 36: 4774-4782
        • Kreimer A.R.
        • Struyf F.
        • Del Rosario-Raymundo M.R.
        • Hildesheim A.
        • Skinner S.R.
        • Wacholder S.
        • et al.
        Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials.
        Lancet Oncol. 2015; 16: 775-786
      5. WHO Strategic Advisory Group of Experts on Immunization Working Group on Human Papillomavirus (HPV) immunization https://www.who.int/immunization/sage/meetings/2019/october/1_HPV_SAGE2019WG_for_SAGE.pdf.